<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">Although mAbs currently are one of the effectiveness class of biopharmaceutical, but the use of them in viral therapy has not yet been extensively routine. In absent of viral vaccines, development neutralizing mAbs against various viruses such as H5N1 influenza virus, human immunodeficiency virus (HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), hepatitis C virus (HCV), Ebola virus, Marburg virus, SARS virus, dengue virus, rabies virus, Hendra virus, Nipah virus, yellow fever virus, and West Nile virus have been described in the past few years demonstrating efficacy of mAbs against viral infection 
 <xref rid="b0295" ref-type="bibr">[59]</xref>. Palivizumab (Synagis) and Ibalizumab (Trogarzo) are two approved monoclonal antibodies against the respiratory syncytial virus (RSV) and HIV, respectively. 
 <xref rid="t0010" ref-type="table">Table 2</xref> shows the main therapeutic mAbs against the target viral.
</p>
